News

Filter

Current filters:

Adcetris

1 to 9 of 19 results

Takeda and Seattle Genetics report positive results from Adcetris

Takeda and Seattle Genetics report positive results from Adcetris

30-09-2014

Seattle Genetics and Japan’s largest drugmaker Takeda Pharmaceutical have reported positive results…

AdcetrisOncologyPharmaceuticalResearchSeattle GeneticsTakeda PharmaUSA

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

26-09-2014

The non-Hodgkin lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia,…

AdcetrisAustraliaChinaGazyvaroIndiaJapanMarkets & MarketingOncologyPharmaceuticalRocheTakeda Pharmaceutical

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Seattle Genetics highlights Adcetris clinical data in the frontline setting

13-10-2013

US biotech firm Seattle Genetics has highlighted multiple Adcetris (brentuximab vedotin) data presentations…

AdcetrisBiotechnologyOncologyResearchSeattle Genetics

Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL

19-03-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) has submitted a supplemental Biologics License Application…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

1 to 9 of 19 results

Back to top